These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

603 related articles for article (PubMed ID: 28464889)

  • 1. Highly divergent patterns of genetic diversity and evolution in proviral quasispecies from HIV controllers.
    de Azevedo SSD; Caetano DG; Côrtes FH; Teixeira SLM; Dos Santos Silva K; Hoagland B; Grinsztejn B; Veloso VG; Morgado MG; Bello G
    Retrovirology; 2017 May; 14(1):29. PubMed ID: 28464889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV Proviral Burden, Genetic Diversity, and Dynamics in Viremic Controllers Who Subsequently Initiated Suppressive Antiretroviral Therapy.
    Omondi FH; Sudderuddin H; Shahid A; Kinloch NN; Jones BR; Miller RL; Tsai O; MacMillan D; Trocha A; Brockman MA; Brumme CJ; Joy JB; Liang R; Walker BD; Brumme ZL
    mBio; 2021 Dec; 12(6):e0249021. PubMed ID: 34781741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ongoing HIV-1 evolution and reservoir reseeding in two elite controllers with genetically diverse peripheral proviral quasispecies.
    de Azevedo SSD; Côrtes FH; Villela LM; Hoagland B; Grinsztejn B; Veloso VG; Morgado MG; Bello G
    Mem Inst Oswaldo Cruz; 2023; 118():e230066. PubMed ID: 37283423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic diversity in the env V1-V2 region of proviral quasispecies from long-term controller MHC-typed cynomolgus macaques infected with SHIVSF162P4cy.
    Capone A; Lo Presti A; Sernicola L; Farcomeni S; Ferrantelli F; Maggiorella MT; Mee ET; Rose NJ; Cella E; Ciccozzi M; Ensoli B; Borsetti A
    J Gen Virol; 2018 Dec; 99(12):1717-1728. PubMed ID: 30311877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV controllers suppress viral replication and evolution and prevent disease progression following intersubtype HIV-1 superinfection.
    de Azevedo SSD; Delatorre E; Côrtes FH; Hoagland B; Grinsztejn B; Veloso VG; Souza TML; Morgado MG; Bello G
    AIDS; 2019 Mar; 33(3):399-410. PubMed ID: 30531316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next-generation sequencing analyses of the emergence and maintenance of mutations in CTL epitopes in HIV controllers with differential viremia control.
    Caetano DG; Côrtes FH; Bello G; Teixeira SLM; Hoagland B; Grinsztejn B; Veloso VG; Guimarães ML; Morgado MG
    Retrovirology; 2018 Sep; 15(1):62. PubMed ID: 30201008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy.
    Hatano H; Delwart EL; Norris PJ; Lee TH; Dunn-Williams J; Hunt PW; Hoh R; Stramer SL; Linnen JM; McCune JM; Martin JN; Busch MP; Deeks SG
    J Virol; 2009 Jan; 83(1):329-35. PubMed ID: 18945778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case report of HIV-1 superinfection in an HIV controller leading to loss of viremia control: a retrospective of 10 years of follow-up.
    Caetano DG; Côrtes FH; Bello G; de Azevedo SSD; Hoagland B; Villela LM; Grinsztejn B; Veloso VG; Guimarães ML; Morgado MG
    BMC Infect Dis; 2019 Jul; 19(1):588. PubMed ID: 31277590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative HIV-1 Proviral Dynamics in Two Individuals That Maintained Viral Replication Control with or without Antiretroviral Therapy following Superinfection.
    de Azevedo SSD; Côrtes FH; Villela LM; Hoagland B; Grinsztejn B; Veloso VG; Morgado MG; Bello G
    Viruses; 2022 Dec; 14(12):. PubMed ID: 36560806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV controllers with different viral load cutoff levels have distinct virologic and immunologic profiles.
    Côrtes FH; Passaes CP; Bello G; Teixeira SL; Vorsatz C; Babic D; Sharkey M; Grinsztejn B; Veloso V; Stevenson M; Morgado MG
    J Acquir Immune Defic Syndr; 2015 Apr; 68(4):377-385. PubMed ID: 25564106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct viral reservoirs in individuals with spontaneous control of HIV-1.
    Jiang C; Lian X; Gao C; Sun X; Einkauf KB; Chevalier JM; Chen SMY; Hua S; Rhee B; Chang K; Blackmer JE; Osborn M; Peluso MJ; Hoh R; Somsouk M; Milush J; Bertagnolli LN; Sweet SE; Varriale JA; Burbelo PD; Chun TW; Laird GM; Serrao E; Engelman AN; Carrington M; Siliciano RF; Siliciano JM; Deeks SG; Walker BD; Lichterfeld M; Yu XG
    Nature; 2020 Sep; 585(7824):261-267. PubMed ID: 32848246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-molecule techniques to quantify and genetically characterise persistent HIV.
    Wang XQ; Palmer S
    Retrovirology; 2018 Jan; 15(1):3. PubMed ID: 29316955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic composition of replication competent clonal HIV-1 variants isolated from peripheral blood mononuclear cells (PBMC), HIV-1 proviral DNA from PBMC and HIV-1 RNA in serum in the course of HIV-1 infection.
    Edo-Matas D; van Gils MJ; Bowles EJ; Navis M; Rachinger A; Boeser-Nunnink B; Stewart-Jones GB; Kootstra NA; van 't Wout AB; Schuitemaker H
    Virology; 2010 Sep; 405(2):492-504. PubMed ID: 20638697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma viral load threshold for sustaining intrahost HIV type 1 evolution.
    Bello G; Casado C; Sandonis V; Alvaro-Cifuentes T; Dos Santos CA; García S; Rodríguez C; Del Romero J; Pilotto JH; Grinsztejn B; Veloso VG; Morgado MG; López-Galíndez C
    AIDS Res Hum Retroviruses; 2007 Oct; 23(10):1242-50. PubMed ID: 17961111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virological characterization of patients treated early is able to control HIV-1 replication after multiple cycles of structured therapy interruption.
    Rozera G; Abbate I; D'Offizi G; Corpolongo A; Narciso P; Vlassi C; Martini F; Calcaterra S; Capobianchi MR
    J Med Virol; 2007 Aug; 79(8):1047-54. PubMed ID: 17597482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic Diversity, Compartmentalization, and Age of HIV Proviruses Persisting in CD4
    Jones BR; Miller RL; Kinloch NN; Tsai O; Rigsby H; Sudderuddin H; Shahid A; Ganase B; Brumme CJ; Harris M; Poon AFY; Brockman MA; Fromentin R; Chomont N; Joy JB; Brumme ZL
    J Virol; 2020 Feb; 94(5):. PubMed ID: 31776273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection and quantification of proviral HIV-1 184 M/V in circulating CD4(+) T cells of patients on HAART with a viremia less than 1,000 copies/ml.
    Mohey R; Jørgensen LB; Møller BK; Black FT; Kjems J; Obel N
    J Clin Virol; 2005 Dec; 34(4):257-67. PubMed ID: 16286049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elite suppressors have low frequencies of intact HIV-1 proviral DNA.
    Kwaa AK; Garliss CC; Ritter KD; Laird GM; Blankson JN
    AIDS; 2020 Mar; 34(4):641-643. PubMed ID: 31895150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus.
    O'Connell KA; Brennan TP; Bailey JR; Ray SC; Siliciano RF; Blankson JN
    J Virol; 2010 Jul; 84(14):7018-28. PubMed ID: 20444904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individuals.
    Weber J; Gibson RM; Sácká L; Strunin D; Hodek J; Weberová J; Pávová M; Alouani DJ; Asaad R; Rodriguez B; Lederman MM; Quiñones-Mateu ME
    AIDS Res Ther; 2017; 14():15. PubMed ID: 28331526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.